Other names: CAP43; CMT4D; DRG-1; DRG1; GC4; HMSNL; NDR1; NMSL; PROXY1; RIT42; RTP; Rit42; TARG1; TDD5 HGNC (Hugo): NDRG1 Location: 8q24.22
Expression
NDRG1 is relatively ubiquitously expressed in normal human cells, and especially highly expressed in prostate, brain, kidney, placenta, ovarian, testicular and intestinal cells. NDRG1 is mostly found in epithelial cells.
Localisation
NDRG1 is primarily a cytoplasmic protein. 47.8% of the NDRG1 is expressed in the cytosol, 26.1% in the nucleus (such as in prostate epithelial cells), and 8.7% in the mitochondria (such as in proximal tubule cells in the kidney). NDRG1 is also found in the adherens junctions. Additionally, in intestinal and lactating breast epithelia NDRG1 is located in the plasma membrane. NDRG1 can also be found in vacuoles, the peroxisome, early and recycling endosomes, and the cytoskeleton.
Function
NDRG1 is reported to be a metastasis suppressor gene which is downregulated in prostate, colon and breast cancers. It has been found to be a Rab4a effector protein that recruits to the recycling endosomes in the Trans Golgi network by binding to the lipid phosphotidylinositol 4-phosphate (PI4P), where it plays a role in the recycling of E-cadherin. NDRG1 also interacts with HSP70. NDRG1 co-localizes with APO A-I and A-II, and may be involved in lipid transport. The function of NDRG1 may be controlled at least in part by phosphorylation. It has also been identified as a stress response gene, upregulated by homocysteine and hypoxia. Hif-1-dependent and independent mechanisms have been implicated in NDRG1 induction. It is also controlled by AP-1 transcription factors. When exposed to stress, for example hypoxia, NDRG1 may play a cytoprotective role in normal healthy cells. There is evidence that NDRG1 is involved in the induction of differentiation. NDRG1 is downregulated under conditions of cell growth. NDRG1 expression peaks in the G1 and G2/M phases, and is lowest in the S phase. NDRG1 is also a microtubule-associated protein, which may play an important role in maintaining spindle structure during cell division. In the Schwann cells, NDRG1 is essential for myelin sheath maintenance. Hence, NDRG1 is a multifunctional protein with roles that may be tissue-and/or cell-type specific. Certain transcription factors such as MYC, ERG1, HIF1-ALPHA bind to the NDRG1 promoter region and regulate its expression. NDRG1 is upregulated during colon epithelial cell differentiation. It is regulated by hormones such as androgens and estradiol. Small molecules such as Nhydroxy-N'-phenol-octane-1,8-diotic acid diamide, calcium ionophores like BAPTA, metal ions such as Nickel and Cobalt, iron chelators and differentiating agents like retinoic acid induce NDRG1 expression. Additionally, NDRG1 is induced during cellular DNA damage and endoplasmic reticulum stress.
Homology
NDRG1 amino acid sequence is 53% homologous to NDRG2, 62% to NDRG3, 62% to NDRG4, and 94% homologous to the mouse analog, Ndr-1 (also known as TDD5). NDRG1 homologs have been found in Helianthus, Caenorhabditis, Xenopus and Drosophilia.
Implicated in

Various solid cancers
Disease Prostate, breast, colon, renal, bladder, pancreatic, hepatic cancer. Prognosis Downregulation of NDRG1 in cancer worsens the prognosis of cancer. There is an inverse relationship in the levels of NDRG1 expression and the Gleason grade of the tumor in prostate cancer. A high PTEN (a tumor suppressor which positively regulates NDRG1) and NDRG1 expression improves survival rates in patients with breast and prostate cancer. In patients with colorectal cancer, the 2 year survival rate for patients with high NDRG1-expression was 82.4%, while for patients with a low NDRG1-expression it was only 69.6%. In pancreatic cancer patients, the median survival time for patients with high NDRG1-expression was 24.7 months, while the median survival time for patients with low NDRG1-expression was only 10.9 months. High expression of NDRG1 in colon tumors was found to correlate with increased resistance to irinotecan.
Oncogenesis
An inverse relationship exists between NDRG1 and the oncogenes N-myc and c-myc, suggesting that members of the MYC family suppress expression of NDRG1. Experimental evidence exist that both N-myc and cmyc downregulate NDRG1 gene expression by directly binding to NDRG1 promoter. NDRG1 is downregulated in colon, breast, prostate and pancreatic neoplasms, by c-myc and N-myc transcription factors. In cancer cells, NDRG1 expression is consistent through all phases in the cell cycle, instead of the biphasic expression in normal cells. PTEN expression is positively related to NDRG1 expression. NDRG1 is induced in cancer cells by histone deacetylase inhibitors and DNA methyl transferase inhibitors indicating that NDRG1 is regulated by chromatin modulation and DNA methylation. Although NDRG1 has been reported to be downregulated in a variety of cancers, it has been shown to be upregulated in hepatic, pancreatic and kidney cancers. Induction of NDRG1 in these tumors is speculated to be in response to tumor stress or hypoxia and NDRG1 is proposed as a marker of tumor hypoxia. However, in pancreatic cancer, cellular differentiation and not hypoxia was demonstrated to be the determining factor for NDRG1 expression. In renal cancer, induction of NDRG1 in the tumor tissue was restricted to infiltrating macrophages and not cancer cells. NDRG1 is suggested to be an early target for p53. Loss of p53 expression in cancer is suggested to reduce NDRG1 expression. However, p53 knockout mice show expression of NDRG1, suggesting that there are other mechanisms regulating NDRG1 levels. NDRG1 expression plays a role in vitro in primary tumor growth in prostate, breast, and bladder cancer: a higher expression of NDRG1 lowers the proliferation rates of these cancers. In pancreatic and bladder cancer cells, this reduction was proven in vivo: in pancreatic cells it was suggested that the reduced proliferation was caused by NDRG1 by modulating tumor stroma and angiogenesis. NDRG1 can recruit onto the recycling endosome in the Trans-Golgi network by binding to phosphotidylinositol 4-phosphate. There, NDRG1 may be involved in the transport of various cargo back to the cells' surface. At the molecular level, NDRG1 may stabilize the E-cadherin molecule by recycling it back to the cells' surface, thereby preventing tumor invasion.
Hereditary motor and sensory neuropathy-Lom (HMSNL) / CharcotMarie-Tooth disease (CMT 4D)
Note Caused by the Gypsy founder mutation, homozygote R148X, also called homozygote C564t. In patients with CMT disease, apart from the R148X mutation, another disease-causing mutation was identified, namely IVS8-1G>A (g.2290787G>A), which results in skipping of exon 9. The homozygote phenotype of this mutation was very closely related to the phenotype of HMSNL patients. Disease A hereditary autosomal recessive disease, caused by demyelination of peripheral nerves. It is the most common form of demyelinating Charcot-Marie-Tooth disease in the Roma population. Prognosis Severe disability in adulthood. It begins consistently in the first decade of life with a gait disorder, followed by upper limb weakness in the second decade and, in most subjects, by deafness setting in in the third decade of life. Sensory loss affecting all modalities is present; both this and the motor involvement predominating distally in the limbs. Skeletal deformity, particularly foot deformities, are frequent.
Atherosclerosis
Note
Patients with HMSNL were found to have a high total cholesterol: HDL-C ratio. Disease Atherosclerosis is an important factor for the development of cardiovascular diseases, like myocardial infarction and angina pectoris. NDRG1 contributes to HDL-C (high-density lipoproteincholesterol) levels most likely by its phosphopantetheine-binding domain interacting with the high-density lipoproteins apolipoprotein A-I and A-II.
